[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642013":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":10,"locations":19,"responsibleParty":40,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":10,"overallStatus":22,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"TACE-HAIC-MTT-PD-1i",null,[12],"Procedure: TACE (transarterial chemoembolization) combined with targeted\u002Fimmunotherapy",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"PROCEDURE","TACE (transarterial chemoembolization) combined with targeted\u002Fimmunotherapy","transarterial chemoembolization",[9],[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Jiayan Ni","RECRUITING","Guangzhou","None Selected","510120","China","CN",{"type":29,"coordinates":30},"Point",[31,32],113.25,23.11667,{"lat":32,"lon":31},[35],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},"Jiayan Ni, MD.","CONTACT","02034070680","jiayan_0129@126.com",{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100642013","tace-andor-haic-combined-with-molecular-targeted-therapy-and-immunotherapy-for-hcc-100642013",false,"NCT07658833","TACE and\u002For HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC","Study of the Safety, Clinical Efficacy and Prognostic Factors of TACE and\u002For HAIC Combined With Molecular-targeted Therapy and Immunotherapy for Hepatocellular Carcinoma","Inclusion Criteria:\n\n* aged 18-80 years\n* Eastern Cooperative Oncology Group (ECOG) performance status score \\\u003C 2\n* maximum tumor diameter ≥ 7 cm\n* IVC\u002FRA TT diagnosed by contrast-enhanced CT \u002F MRI before study treatment\n* unresectable HCC (uHCC) confirmed by a specialized multidisciplinary team\n* liver function of Child-Pugh class A or B\n\nExclusion Criteria:\n\n* with other malignancies\n* prior anti-tumor therapy\n* history of drug allergy\n* autoimmune diseases\n* digestive hemorrhage of any grade\n* insufficient renal, bone marrow, or coagulation function","ALL","18 Years","75 Years",{"count":53,"type":54},120,"ESTIMATED","OBSERVATIONAL","The safety, clinical efficacy and prognostic factors of transcatheter arterial chemoembolization (TACE) and\u002For hepatic artery infusion chemotherapy (HAIC) combined with targeted immunotherapy for primary hepatocellular carcinoma (HCC) require further in-depth study. This research aims to evaluate the safety, clinical efficacy and prognostic factors of TACE and\u002For HAIC combined with targeted immunotherapy for hepatocellular carcinoma.\n\nWe are going to compare and analyze local tumor response, survival outcomes, prognostic factors and adverse events. Tumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version. Adverse events were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. This study intends to include the targeted and immunotherapy applied, mainly including: lenvatinib, sorafenib, apatinib, bevacizumab, etc.; pembrolizumab, carfilzomib, sintilimab and teprotumumab, etc.",[58],"Hepatocellular Carcinoma (HCC)","2026-06-15",{"date":61,"type":62},"2026-06-22","ACTUAL",{"date":64,"type":54},"2026-07-01",{"date":66,"type":54},"2028-06-30",{"name":5,"class":6},1]